HOVON 185: Pharmacokinetic boosting of ibrutinib with ritonavir in patients with chronic lymphocytic leukemia, lymphoplasmacytic- and mantle cell lymphoma
Sponsor: Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
Phase: 2
Disease: Chronic lymphocytic leukemia, Lymphoplasmacytic lymphoma, Mantle cell lymphoma
EU trial number: 2026-526101-15-00
Population: Adults with chronic lymphocytic leukemia, lymphoplasmacytic lymphoma, or mantle cell lymphoma who have received ibrutinib for more than 60 days without dose reduction, have WHO performance status 0–2, and have adequate renal and hepatic function.
Register Investigator Interest
Interested in offering this trial to suitable patients?